Matthew B. Klein net worth and biography

Matthew Klein Biography and Net Worth

COO of PTC Therapeutics

Dr. Matthew B. Klein, MD, MS, FACS is Chief Development Officer at PTC Therapeutics, Inc. Prior to joining PTC, Dr. Klein was CEO and Chief Medical Officer of BioElectron Technology Corporation, a biotechnology company focused on development of redox active small molecules for mitochondrial disease and related disorders of oxidative stress. Prior to joining BioElectron, Dr. Klein was the Auth-Washington Research Foundation Chair of Restorative Burn Surgery at the University of Washington. Dr. Klein completed his undergraduate degree at the University of Pennsylvania where he graduated summa cum laude and Phi Beta Kappa, and received his MD degree with honors from Yale University.

What is Matthew B. Klein's net worth?: The estimated net worth of Matthew B. Klein is at least $26.08 million as of August 4th, 2026. Dr. Klein owns 383,868 shares of PTC Therapeutics stock worth more than $26,076,153 as of September 17th. This net worth estimate does not reflect any other assets that Dr. Klein may own. Learn More about Matthew B. Klein's net worth.
How do I contact Matthew B. Klein?: The corporate mailing address for Dr. Klein and other PTC Therapeutics executives is 500 Warren Corporate Center Drive, Warren, NJ, 07059. PTC Therapeutics can also be reached via phone at (908) 222-7000 and via email at [email protected]. Learn More on Matthew B. Klein's contact information.
Has Matthew B. Klein been buying or selling shares of PTC Therapeutics?: During the last quarter, Matthew B. Klein has sold $705,722.44 in PTC Therapeutics stock. Most recently, Matthew B. Klein sold 10,292 shares of the business's stock in a transaction on Tuesday, August 4th. The shares were sold at an average price of $68.57, for a transaction totalling $705,722.44. Following the completion of the sale, the chief executive officer now directly owns 383,868 shares of the company's stock, valued at $26,321,828.76. Learn More on Matthew B. Klein's trading history.
Who are PTC Therapeutics' active insiders?: PTC Therapeutics' insider roster includes Neil Almstead (Insider), Mark Boulding (VP), Lee Golden (Chief Medical Officer), Pierre Gravier (CFO), Emily Hill (CFO), Allan Jacobson (Director), Matthew Klein (COO), Stephanie Okey (Director), Eric Pauwels (Insider), Stuart Peltz (CEO), Emma Reeve (Director), Michael Schmertzler (Director), Mary Smith (Director), David Southwell (Director), Dawn Svoronos (Director), Christine Utter (CAO), Alethia Young (Chief Financial Officer, Bicycle Therapeutics), and Jerome Zeldis (Director). Learn More on PTC Therapeutics' active insiders.
Are insiders buying or selling shares of PTC Therapeutics?: During the last twelve months, insiders at the biopharmaceutical company sold shares 87 times. They sold a total of 800,799 shares worth more than $60,489,739.65. The most recent insider tranaction occured on September, 9th when Director Michael Schmertzler sold 10,000 shares worth more than $678,400.00. Insiders at PTC Therapeutics own 5.3% of the company. Learn More about insider trades at PTC Therapeutics.
Information on this page was last updated on 9/9/2026.

Matthew B. Klein Insider Trading History at PTC Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/4/2026	Sell	10,292	$68.57	$705,722.44	383,868
5/14/2026	Sell	12,572	$72.95	$917,127.40	393,998
4/21/2026	Sell	2,850	$70.91	$202,093.50	394,070
3/12/2026	Sell	2,662	$64.08	$170,580.96	396,920
2/18/2026	Sell	7,371	$69.36	$511,252.56	387,082
1/8/2026	Sell	2,514	$76.45	$192,195.30	394,453
1/7/2026	Sell	3,016	$77.48	$233,679.68	396,967
1/6/2026	Sell	5,149	$76.95	$396,215.55	399,983
12/30/2025	Sell	8,089	$76.64	$619,940.96	341,875
12/2/2025	Sell	3,428	$79.07	$271,051.96	349,964
8/5/2025	Sell	10,739	$51.74	$555,635.86	337,767
4/22/2025	Sell	2,804	$48.74	$136,666.96	273,234
12/31/2024	Sell	8,279	$45.16	$373,879.64	217,528
4/19/2024	Sell	3,361	$24.89	$83,655.29	225,807
1/8/2024	Sell	2,237	$28.64	$64,067.68	165,918
1/5/2024	Sell	10,107	$27.15	$274,405.05	168,155
4/18/2023	Sell	1,211	$52.04	$63,020.44	102,645
1/11/2023	Sell	2,244	$44.36	$99,543.84	77,856
1/9/2023	Sell	731	$41.66	$30,453.46	82,373
4/19/2022	Sell	897	$42.52	$38,140.44	56,564
1/15/2021	Sell	4,300	$69.09	$297,087.00	23,609
1/7/2021	Sell	3,886	$68.98	$268,056.28	24,809

Matthew B. Klein Buying and Selling Activity at PTC Therapeutics

PTC Therapeutics Company Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

Today's Range

Now: $68.00

$67.22

$68.84

50 Day Range

MA: $72.66

$65.65

$84.85

2 Week Range

Now: $68.00

$57.74

$90.87

Volume

1,115,267 shs

Average Volume

808,834 shs

Market Capitalization

$5.68 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.55